Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04578600
Title CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Joseph Tuscano

MALT lymphoma

hairy cell leukemia

marginal zone B-cell lymphoma

lymphoplasmacytic lymphoma

mantle cell lymphoma

follicular lymphoma

chronic lymphocytic leukemia/small lymphocytic lymphoma

B-cell lymphoma


Azacitidine + Lenalidomide + Obinutuzumab

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.